Pluri Inc

4DX

Company Profile

  • Business description

    Pluri Inc is a biotechnology company engaged in the research, development, and manufacturing of cell-based products, as well as the commercialization of cell therapeutics and related technologies aimed at delivering solutions across a range of industries, including regenerative medicine, immunotherapy, food tech, CDMO, and AgTech. The company uses its 3D cell expansion technology platform to develop placenta-based cell therapy product candidates (PLX-PAD and PLX-R18) for the treatment of inflammatory, muscle injuries, and hematologic conditions. In addition, it offers CDMO services through PluriCDMO, has launched a novel immunotherapy platform, and is engaged in developing cultivated, cell-cultured coffee and meat.

  • Contact

    MATAM Advanced Technology Park
    Building No. 5
    Haifa3508409
    ISR

    T: +972 747108600

    E: [email protected]

    https://www.pluri-biotech.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    30 June 2026

    Employees

    142

Stocks News & Analysis

stocks

Undervalued ASX share with pathway to positive cash flow

Higher sales and a new loan facility increase our conviction.
stocks

Taiwan Semiconductor earnings: Buoyant guidance backed by voracious AI demand

We’ve raised our fair value estimate of Taiwan Semiconductor stock.
stocks

Ahead of earnings, is Netflix a buy, a sell, or fairly valued?

Watching sales growth and the potential for a major acquisition, here’s what we think of Netflix stock.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries9,226.7045.900.50%
CAC 408,258.9454.18-0.65%
DAX 4025,297.1355.26-0.22%
Dow JONES (US)49,359.3383.11-0.17%
FTSE 10010,235.293.65-0.04%
HKSE26,844.9678.66-0.29%
NASDAQ23,515.3914.63-0.06%
Nikkei 22553,936.17174.33-0.32%
NZX 50 Index13,718.1058.310.43%
S&P 5006,940.014.46-0.06%
S&P/ASX 2008,903.9048.100.54%
SSE Composite Index4,101.9110.69-0.26%

Market Movers